ADSTEM / EHL Bio - LARVOL DELTA

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis (clinicaltrials.gov) - P2 | N=118 | Active, not recruiting | Sponsor: EHL Bio Co., Ltd. | Trial completion date: May 2027 ➔ Oct 2027

Trial completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis (clinicaltrials.gov) - P2 | N=118 | Active, not recruiting | Sponsor: EHL Bio Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Feb 2025 ➔ Jan 2023

Enrollment closed • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis (clinicaltrials.gov) - P=N/A | N=11 | Completed | Sponsor: EHL Bio Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis (clinicaltrials.gov) - P=N/A; N=11; Active, not recruiting; Sponsor: EHL Bio Co., Ltd.; Trial primary completion date: Aug 2021 ➔ Aug 2022

Clinical • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis (clinicaltrials.gov) - P=N/A; N=11; Active, not recruiting; Sponsor: EHL Bio Co., Ltd.; Trial primary completion date: Sep 2022 ➔ Aug 2021

Clinical • Trial primary completion date

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis (clinicaltrials.gov) - P2; N=118; Recruiting; Sponsor: EHL Bio Co., Ltd.

Clinical • New P2 trial